Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
AACR & ASCO 2021 – Midyear Review
Year in Review
Phase 2 Study of D-0316 in Patients with Advanced NSCLC and EGFR T790M Mutation
AACR & ASCO 2021 – Midyear Review
D-0316, a third-generation EGFR tyrosine kinase inhibitor (TKI), has antitumor activity and acceptable toxicity in patients with
EGFR
T790M–positive non–small-cell lung cancer (NSCLC) who progressed after EGFR-TKI treatment.
Read More ›
Year in Review
Phase 2 Study of Osimertinib + Oleclumab in Progressive T790M-Negative EGFR-Mutated NSCLC
AACR & ASCO 2021 – Midyear Review
The combination of a novel CD73 inhibitor, oleclumab, and osimertinib was well tolerated and effective in patients with advanced
EGFR
-mutated and T790M-negative non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Phase 1 Study of Telisotuzumab Vedotin in Patients with c-Met–Mutated Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
Telisotuzumab vedotin (teliso-V), an anti–c-Met antibody conjugated with a tubulin inhibitor payload, is active in selected patients with advanced c-Met–positive non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
With 2 years’ minimum follow-up, first-line use of nivolumab, ipilimumab, and chemotherapy offers durable survival relative to chemotherapy alone in patients with advanced non–small-cell lung cancer.
Read More ›
Year in Review
Rucaparib in High Genomic Loss of Heterozygosity and/or BRCA1/2-Mutated NSCLC (Lung-MAP Sub-Study, S1900A)
AACR & ASCO 2021 – Midyear Review
As a marker of homologous recombination deficiency, genomic loss of heterozygosity does not predict efficacy of rucaparib in advanced non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Four-Year Update from CheckMate-227 Study of Nivolumab plus Ipilimumab in Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
After 4 years’ follow-up, nivolumab combined with ipilimumab provides durable, long-term survival benefit compared with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression.
Read More ›
Year in Review
Racial Disparities in Biomarker Testing and Clinical Trial Enrollment in NSCLC
AACR & ASCO 2021 – Midyear Review
Rates of comprehensive biomarker testing and clinical trial participation were significantly lower for black patients with advanced non–small-cell lung cancer (NSCLC) in the United States compared with white patients.
Read More ›
Year in Review
Capmatinib in MET Exon 14–Mutated Advanced NSCLC (GEOMETRY Mono-1 Study)
AACR & ASCO 2021 – Midyear Review
Capmatinib offers deep and durable responses with a manageable toxicity for patients with
MET
exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy.
Read More ›
Videos
Year in Review
Combination Therapies and New Molecular Targets—Presentations from AACR 2021
By
David Spigel, MD
AACR & ASCO 2021 – Midyear Review
Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents.
Read More ›
Videos
Year in Review
Practice-Changing Data in NSCLC from ASCO 2021
By
Mark A. Socinski, MD
AACR & ASCO 2021 – Midyear Review
Dr Mark Socinski provides his insights into important new data on
EGFR
inhibitors and immunotherapy in the first-line setting for NSCLC.
Read More ›
Page 2 of 3
1
2
3
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Supported through funding by
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us